Profile data is unavailable for this security.
About the company
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
- Revenue in USD (TTM)495.14m
- Net income in USD30.32m
- Incorporated2006
- Employees824.00
- LocationVeracyte Inc6000 Shoreline Court, Suite 300SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 243-6300
- Fax+1 (650) 243-6301
- Websitehttps://www.veracyte.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcus Biosciences Inc | 240.00m | -341.00m | 2.46bn | 627.00 | -- | 4.92 | -- | 10.25 | -3.43 | -3.43 | 2.38 | 4.07 | 0.2156 | -- | 13.71 | 382,775.10 | -30.64 | -16.91 | -38.40 | -19.76 | -- | -- | -142.08 | -97.85 | -- | -- | 0.1835 | -- | 120.51 | 76.65 | 7.82 | -- | 25.53 | -- |
| Beam Therapeutics Inc | 55.70m | -414.64m | 2.51bn | 483.00 | -- | 2.59 | -- | 45.05 | -4.43 | -4.43 | 0.5936 | 9.53 | 0.0449 | -- | -- | 115,323.00 | -33.41 | -24.98 | -38.87 | -29.69 | -- | -- | -744.41 | -241.53 | -- | -- | 0.00 | -- | -83.18 | 412.30 | -184.28 | -- | -6.50 | -- |
| Adaptive Biotechnologies Corp | 252.75m | -79.61m | 2.51bn | 619.00 | -- | 12.29 | -- | 9.95 | -0.5381 | -0.5381 | 1.65 | 1.34 | 0.4818 | 6.50 | 5.90 | 408,326.30 | -15.17 | -21.92 | -18.12 | -24.85 | 71.84 | 64.77 | -31.49 | -119.25 | 3.26 | -55.47 | 0.3923 | -- | 5.10 | 16.04 | 29.19 | -- | -20.03 | -- |
| Spyre Therapeutics Inc | 0.00 | -148.97m | 2.56bn | 95.00 | -- | 6.66 | -- | -- | -2.55 | -2.55 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -32.19 | -75.44 | -36.25 | -85.33 | -- | -- | -- | -3,540.66 | -- | -- | 0.00 | -- | -100.00 | -- | 38.60 | -- | -- | -- |
| Travere Therapeutics Inc | 435.83m | -88.54m | 2.64bn | 385.00 | -- | 35.84 | -- | 6.05 | -1.08 | -1.08 | 4.80 | 0.8223 | 0.8357 | 1.74 | 8.06 | 1,132,018.00 | -16.98 | -41.64 | -24.67 | -51.97 | 97.63 | 95.90 | -20.32 | -175.36 | 2.71 | -- | 0.8089 | -- | 60.55 | 5.87 | 14.80 | -- | 45.42 | -- |
| Immunome Inc | 9.68m | -222.74m | 2.65bn | 118.00 | -- | 8.34 | -- | 273.58 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.67bn | 240.00 | -- | 3.41 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Veracyte Inc | 495.14m | 30.32m | 2.76bn | 824.00 | 91.96 | 2.19 | 52.30 | 5.57 | 0.3791 | 0.3791 | 6.21 | 15.91 | 0.3747 | 7.66 | 10.25 | 600,899.30 | 2.29 | -4.19 | 2.43 | -4.43 | 68.53 | 66.82 | 6.12 | -13.70 | 5.94 | -- | 0.00 | -- | 23.46 | 29.93 | 132.44 | -- | 32.57 | -- |
| Viridian Therapeutics Inc | 70.79m | -301.97m | 2.78bn | 143.00 | -- | 7.64 | -- | 39.33 | -3.72 | -3.72 | 0.8716 | 6.12 | 0.105 | -- | 2.02 | 495,028.00 | -44.77 | -50.26 | -48.05 | -53.97 | -- | -- | -426.58 | -12,930.56 | -- | -- | 0.0399 | -- | -3.82 | -41.64 | -13.55 | -- | 43.49 | -- |
| Ideaya Biosciences Inc | 214.83m | -160.74m | 2.79bn | 131.00 | -- | 2.55 | -- | 12.96 | -1.85 | -1.85 | 2.43 | 12.46 | 0.1772 | -- | -- | 1,639,954.00 | -13.26 | -22.71 | -13.86 | -24.48 | -- | -- | -74.82 | -411.78 | -- | -- | 0.00 | -- | -70.07 | -- | -142.98 | -- | 23.31 | -- |
| Vera Therapeutics Inc | 0.00 | -251.94m | 2.87bn | 224.00 | -- | 6.56 | -- | -- | -3.98 | -3.98 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -56.87 | -54.55 | -61.62 | -60.06 | -- | -- | -- | -- | -- | -- | 0.1576 | -- | -- | -- | -58.50 | -- | 50.71 | -- |
| Edgewise Therapeutics Inc | 0.00 | -157.24m | 2.88bn | 136.00 | -- | 5.15 | -- | -- | -1.58 | -1.58 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -28.73 | -26.21 | -29.83 | -27.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.60 | -- | 48.78 | -- |
| Disc Medicine Inc | 0.00 | -181.11m | 2.96bn | 84.00 | -- | 4.78 | -- | -- | -5.35 | -5.35 | 0.00 | 16.38 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -33.75 | -- | -- | -- | -- | -- | -- | -- | 0.0481 | -- | -- | -- | -43.08 | -- | -- | -- |
| Viking Therapeutics Inc | 0.00 | -237.39m | 2.97bn | 50.00 | -- | 4.15 | -- | -- | -2.12 | -2.12 | 0.00 | 6.34 | 0.00 | -- | -- | 0.00 | -28.31 | -22.44 | -29.21 | -23.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -28.02 | -- | -- | -- |
| Legend Biotech Corp (ADR) | 908.96m | -239.70m | 3.08bn | 2.90k | -- | 3.05 | -- | 3.39 | -1.30 | -1.30 | 4.94 | 5.48 | 0.5271 | 13.60 | 936.59 | 349,601.20 | -13.90 | -30.18 | -17.47 | -36.54 | 60.55 | -- | -26.37 | -154.41 | 2.80 | -1.36 | 0.2886 | -- | 119.97 | 59.91 | 65.84 | -- | -18.48 | -- |
| Denali Therapeutics Inc | 0.00 | -498.74m | 3.12bn | 517.00 | -- | 3.17 | -- | -- | -2.91 | -2.91 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -39.75 | -16.91 | -42.77 | -19.81 | -- | -- | -- | -135.24 | -- | -- | 0.006 | -- | -100.00 | -- | -191.12 | -- | -2.35 | -- |
Data as of Feb 06 2026. Currency figures normalised to Veracyte Inc's reporting currency: US Dollar USD
64.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 11.32m | 14.32% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.84m | 9.92% |
| Artisan Partners LPas of 30 Sep 2025 | 7.37m | 9.32% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 5.75m | 7.27% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 4.20m | 5.31% |
| ARK Investment Management LLCas of 31 Dec 2025 | 3.89m | 4.92% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 3.07m | 3.89% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 3.00m | 3.79% |
| ArrowMark Colorado Holdings LLCas of 30 Sep 2025 | 2.55m | 3.22% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.89m | 2.39% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
